SpaceX stock surged over 17% recently, trading near $173.30 as of October 6, 2026. Goldman Sachs raised its 12-month price target to $230, expecting a 32.7% upside driven by strong AI segment growth and expanding space opportunities. Morgan Stanley also maintains a 'Buy' rating, with analyst consensus targeting around $235 by late 2027. The stock's rise is backed by solid fundamentals including Starship development and rising AI product demand, suggesting sustained momentum rather than a short-term bounce.
SpaceX stock recently surged over 17%, trading near $173.30 as of October 6, 2026. For readers following the Technology sector, here is Pluang's market snapshot as of Oct 06, 2026 17:51 WIB: out of 150 priced US Technology stocks, 120 rose and 28 fell today. Notable movers include VERI at USD 0.75 (+3.38%), ZS at USD 206.97 (+2.56%), and VNET at USD 5.58 (+2.48%), with typical hold times ranging from 12 to 41 days and varied Pluang order activity percentages.
Over the past six months, Costco's stock has fallen by 10%, contrasting with the S&P 500's 17% gain. This decline has sparked debate on whether Costco's shares, now trading under $900, represent a buying opportunity. Investors are weighing if the pri...
Elon Musk has confirmed that his company is in discussions with Terafab, marking a potential new chip manufacturing partner alongside Intel, which has been the only named chip partner until now. This development could diversify the supply chain and e...
Barrick Gold resolved its dispute with Newmont, receiving a $1.95 billion payment and approval to list its North American gold assets separately. This move aims to unlock hidden value, particularly in Nevada, while leaving African and copper assets o...
Hyperscale Data held about $18.5 million in Bitcoin and $37.5 million in cash as of late September, totaling $56 million in assets, which is 153% of its market cap. The company stopped Bitcoin mining at its Michigan facility on September 1 to convert...
Viking Therapeutics has launched Part 2 of a study exploring oral and subcutaneous dosing regimens of VK2735, a dual GLP-1/GIP receptor agonist, to maintain weight loss in adults with obesity. This randomized, placebo-controlled trial follows positiv...
